02344nas a2200193 4500000000100000008004100001100002600042700001200068700001200080700001400092700001300106700001300119700001300132700001500145245010100160250001500261520182300276020005102099 2015 d1 aSherrington Catherine1 aLord S.1 aFung V.1 aHoward K.1 aFarag I.1 aClose J.1 aHayes A.1 aCanning C.00aEconomic evaluation of a falls prevention exercise program among people With Parkinson's disease a2015/09/243 a

OBJECTIVE: The aim of this study was to determine the cost-effectiveness of a 6-month minimally supervised exercise program for people with PD. METHODS: An economic analysis was conducted alongside a randomized, controlled trial in which 231 people age 40 years and over with PD were randomized into a usual care control group or an exercise group. Cost-effectiveness was estimated using incremental cost per fall prevented (using falls calendars) as the primary analysis and cost per extra person avoiding mobility deterioration (defined as an improvement or no change in the 12-point Short Physical Performance Battery Score between baseline and 6 month). A cost-utility analysis using the Short Form-6D was also performed. Uncertainty was represented using cost-effectiveness scatter plots and acceptability curves. Planned subgroup analyses for the low-disease-severity group were also undertaken. RESULTS: All results are reported in Australian dollars ($A). The average cost of the intervention was $A1,010 per participant. Incremental cost-effectiveness of the program relative to usual care was $A574 per fall prevented, $A9,570 per extra person avoiding mobility deterioration, and $A338,800 per quality-adjusted life year gained. The intervention had an 80% probability of being cost-effective, relative to the control, at a threshold of $A2,000 per fall prevented. Subgroup analyses for the low-disease-severity group indicate the program to be dominant, that is, less costly and more effective than usual care for all health outcomes. CONCLUSION: The exercise intervention appeared cost-effective with regard to fall prevention in the whole sample and cost saving in the low disease severity group, when compared with usual care. (c) 2015 International Parkinson and Movement Disorder Society.

 a1531-8257 (Electronic)
0885-3185 (Linking)